Merck Reports Positive CHMP Recommendation For KEYTRUDA Plus Padcev

Merck’s KEYTRUDA in combination with Padcev received a positive opinion from the European Medicines Agency’s CHMP, clearing an important step toward EU approval in the neoadjuvant setting. The decision is supportive for Merck’s oncology franchise and could expand the therapy’s label, though the article only reports a recommendation rather than final approval.

Analysis

Merck’s KEYTRUDA in combination with Padcev received a positive opinion from the European Medicines Agency’s CHMP, clearing an important step toward EU approval in the neoadjuvant setting. The decision is supportive for Merck’s oncology franchise and could expand the therapy’s label, though the article only reports a recommendation rather than final approval.